Practical Considerations for Selecting and Administering Treatment in mHSPC

FDA ODAC Votes to Restrict Olaparib/Abiraterone Use to BRCA+ mCRPC

Oncology Peer Review On-The-Go: Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer

Oncology Peer Review On-The-Go: Successful Diagnosis and Treatment of Occult Prostate Cancer Despite Multiple Negative Prostate Biopsies and Negative Prostate MRIs

FDA ODAC Votes to Restrict Olaparib/Abiraterone Use to BRCA+ mCRPC

Oncology Peer Review On-The-Go: Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer

177Lu-PNT2002 Received FDA Fast Track Designation for Metastatic CRPC

Niraparib/DAT Abiraterone Receives EU Approval in Prostate Cancer Subtype

PSA Decline With Apalutamide Yields Improved Survival in Prostate Cancer

May 10th 2023

Oncology Peer Review On-The-Go: Successful Diagnosis and Treatment of Occult Prostate Cancer Despite Multiple Negative Prostate Biopsies and Negative Prostate MRIs

FDA ODAC Votes to Restrict Olaparib/Abiraterone Use to BRCA+ mCRPC

Oncology Peer Review On-The-Go: Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer

177Lu-PNT2002 Received FDA Fast Track Designation for Metastatic CRPC

Niraparib/DAT Abiraterone Receives EU Approval in Prostate Cancer Subtype

PSA Decline With Apalutamide Yields Improved Survival in Prostate Cancer

Related Content

A post hoc analysis of the phase 3 TITAN trial highlights an association between PSA decline and survival among patients with metastatic castration-sensitive prostate cancer who were treated with apalutamide plus androgen deprivation therapy.

May 10th 2023

Oncology Peer Review On-The-Go: Successful Diagnosis and Treatment of Occult Prostate Cancer Despite Multiple Negative Prostate Biopsies and Negative Prostate MRIs

A post hoc analysis of the phase 3 TITAN trial highlights an association between PSA decline and survival among patients with metastatic castration-sensitive prostate cancer who were treated with apalutamide plus androgen deprivation therapy.

FDA ODAC Votes to Restrict Olaparib/Abiraterone Use to BRCA+ mCRPC

Podcast

Judd W. Moul, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on the treatment of a patients with evidence of prostate cancer despite multiple negative prognostic tests.

During the ODAC meeting, members voted to restrict the use of olaparib plus abiraterone and prednisone or prednisolone to patients with BRCA-mutated metastatic castration-resistant prostate cancer.

Oncology Peer Review On-The-Go: Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer

During the ODAC meeting, members voted to restrict the use of olaparib plus abiraterone and prednisone or prednisolone to patients with BRCA-mutated metastatic castration-resistant prostate cancer.

177Lu-PNT2002 Received FDA Fast Track Designation for Metastatic CRPC

Podcast

Muhammad Rafay Khan Niazi, MD, and Alexander Bershadskiy, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on the use of PARP inhibitors as maintenance therapy for certain patients with metastatic castration-resistant prostate cancer.

Niraparib/DAT Abiraterone Receives EU Approval in Prostate Cancer Subtype

The phase 3 SPLASH trial will assess the benefit of 177Lu-PNT2002 in patients with PSMA-expressing metastatic castration-resistant prostate cancer.

Data from the phase 3 MAGNITUDE study support the European Commission’s approval of niraparib plus abiraterone acetate dual action tablets in BRCA-mutated metastatic castration-resistant prostate cancer.